

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016

SUNTEC SINGAPORE CONVENTION
& EXHIBITION CENTER

SINGAPORE

PROGRAM
AND

SCHEDULE OF EVENTS



ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS

Saturday

3

SATURDAY, 3 SEPTEMBER

8:00AM-12:00PM **SHORT COURSE MORNING SESSION** *Separate Registration Required (Please see ISPOR Registration)*

INTRODUCTION TO PHARMACOECONOMICS/HEALTH ECONOMICS **Room 324**

INTRODUCTION TO MODELING **Room 327**

NEW! HEALTH CARE DATA AND INFORMATICS **Room 325**

ELEMENTS OF PHARMACEUTICAL/BIOTECH PRICING **Room 326**

INTRODUCTION TO HEALTH TECHNOLOGY ASSESSMENT **Room 323**

COST EFFECTIVENESS ANALYSIS ALONGSIDE CLINICAL TRIALS **Room 300-301**

12:00PM-1:00PM **LUNCH** *Attendees on their own*

1:00PM-5:00PM **SHORT COURSE AFTERNOON SESSION** *Separate Registration Required (Please see ISPOR Registration)*

MODELING: DESIGN AND STRUCTURE OF A MODEL **Room 324**

PATIENT-REPORTED OUTCOMES MEASURES (PROMS): CROSS-CULTURAL DEVELOPMENT AND VALIDATION **Room 327**

RETROSPECTIVE DATABASE DESIGN AND ANALYSIS **Room 326**

META-ANALYSIS AND SYSTEMATIC LITERATURE REVIEW IN COMPARATIVE EFFECTIVENESS RESEARCH **Room 323**

NEW! CASE STUDIES IN PHARMACEUTICAL / BIOTECH PRICING II – ADVANCED **Room 300-301**

CASE STUDIES IN HEALTH TECHNOLOGY ASSESSMENT **Room 325**

5:15PM-6:15PM **EDUCATIONAL SYMPOSIUM** **Room 328-329**

VALUE OF NEW DIRECT-ACTING ANTIVIRALS TO TREAT HEPATITIS C INFECTION

Sponsored by AbbVie

abbvie

6:30PM-7:30PM **EDUCATIONAL SYMPOSIUM** **Room 328-329**

PORTFOLIO MANAGEMENT—A NEW APPROACH IN HEALTH ECONOMICS TO SUPPORT DECISION MAKERS ON VACCINE INTRODUCTION AT THE NATIONAL LEVEL

Sponsored by GSK

gsk

7:45PM-8:45PM **EDUCATIONAL SYMPOSIUM** **Room 328-329**

ENGAGING PATIENTS IN HEALTH TECHNOLOGY ASSESSMENT AND ACCESS DECISIONS TO IMPROVE QUALITY OF PATIENT CARE

Sponsored by Amgen, Inc.

AMGEN®

9:00PM-10:30PM **WELCOME RECEPTION** **Room 308-310**

All attendees welcome, no separate registration required. Please join us for a traditional performance to open the reception followed by an opportunity to network with colleagues while enjoying a drink and appetizers.

Co-Sponsored by Merck Serono

MERCK

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: SUNDAY, 4 SEPTEMBER

Sunday

4

SUNDAY, 4 SEPTEMBER

8:00AM-12:00PM **SHORT COURSE MORNING SESSION** *Separate Registration Required (Please see ISPOR Registration)*

STATISTICAL CONSIDERATIONS IN HEALTH ECONOMIC EVALUATIONS **Room 327**
HEALTH-RELATED QUALITY OF LIFE (HRQOL) WEIGHTS FOR ECONOMIC EVALUATIONS **Room 324**
NETWORK META-ANALYSIS AND INDIRECT TREATMENT COMPARISONS **Room 323**
BUDGET IMPACT AND COST ANALYSIS **Room 326**
RISK-SHARING/PERFORMANCE-BASED SCHEMES FOR DRUGS & MEDICAL DEVICES **Room 325**
NEW! HEALTH CARE SYSTEMS IN ASIA **Room 300-301**

12:00PM-1:00PM **LUNCH** *Attendees on their own*

12:30PM-7:30PM **RESEARCH POSTER PRESENTATIONS – SESSION I** *Nicoll 1-3*

1:00PM-1:30PM **WELCOME Summit 1**

WELCOME FROM ISPOR ASIA CONSORTIUM EXECUTIVE COMMITTEE CHAIR

Isao Kamae, MD, DrPH, 2016-2018 ISPOR Asia Consortium Executive Committee Chair and Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan



Kamae

WELCOME FROM CONFERENCE CO-CHAIRS

Wai Keung Chui, PhD, Associate Professor, Department of Pharmacy, National University of Singapore, Singapore

Syed Aljunid, MD, PhD, Professor, Health Economics and Public Health Medicine & Head, International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia

Ahmad Fuad Afdhal, PhD, Director, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia



Chui



Aljunid



Afdhal

WELCOME FROM ISPOR PRESIDENT

Lou Garrison, PhD, 2016-2017 ISPOR President and Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, USA



Garrison

WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTOR

Nancy S. Berg, BSc, CEO & Executive Director, ISPOR, Lawrenceville, NJ, USA



Berg

1:30PM-1:45PM **OPENING SPEECH Summit 1**

John CW Lim, Deputy Director of Medical Services (Industry & Research Matters), Ministry of Health and Executive Director of Centre of Regulatory Excellence, Duke-NUS Medical School, Singapore



Lim

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: SUNDAY, 4 SEPTEMBER

1:45PM-3:15PM **FIRST PLENARY SESSION Summit 1**

FIRST PLENARY SESSION: HEALTH TECHNOLOGY ASSESSMENT AND HEALTH POLICY: RECENT DEVELOPMENTS ACROSS ASIA

Health systems in Asia are undergoing a period of rapid change as they struggle to cope with immediate challenges, such as expanding elderly populations, growing demand for high-quality health care and the need to address inequitable access to health care. In light of these issues, health technology assessment (HTA) will be essential as a means to inform evidence-based decisions and ensure efficient use of scarce resources. This session will provide insight into the current status of HTA and related health policy in Asia, sharing perspectives and experiences, lessons learned, and future trends.

Moderator: Syed Aljunid, MD, PhD, Professor, Health Economics and Public Health Medicine & Head, International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia

Speakers:

Visanu Thamlikitkul, MD, Professor, Department of Medicine & Head, Division of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Siriraj Hospital at Mahidol University and Former Chair, Subcommittee of National List of Essential Medicines, Bangkok, Thailand

Takashi Fukuda, PhD, Director, Department of Health and Welfare Services, National Institute of Public Health, Saitama, Japan


Tae-jin Lee, MPH, PhD, Professor, Health Economics, School of Public Health,

Seoul National University and President, Korea Association of Health Economics and Policy, Seoul, South Korea

Kwong Hoe Ng, Head, Evaluation and Appraisal, Agency for Care Effectiveness, Ministry of Health, Singapore



Aljunid



Thamlikitkul



Fukuda



Lee



Ng

3:15PM-3:45PM **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Nicoll 1-3**

3:45PM-4:45PM **ISSUE PANELS – SESSION I**

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP1: SETTING BUDGET IMPACT ANALYSIS THRESHOLDS IN ASIA AND ABROAD: IS THRESHOLD TRANSPARENCY PRUDENT AND FOR WHOM? Summit 1

Moderator: Piyameth Dilokthornsakul, PharmD, PhD, Center of Pharmaceutical Outcomes Research, Naresuan University, Muang, Phitsanulok, Thailand

Panelists: Jonathan D. Campbell, PhD, Assistant Professor, Center for Pharmaceutical Outcomes Research, University of Colorado Anschutz Medical Campus, Denver, CO, USA; **Jeonghoon Ahn, PhD**, Associate Professor, Department of Health Convergence, Ewha Womans University, Seoul, South Korea; **Nathorn Chaikunapruk, PharmD, PhD**, Professor of Health Economics, School of Pharmacy, Monash University Malaysia, Selangor Darul Ehsan, Malaysia

IP2: GROWING DEMANDS FOR HTA IN ASIA: HOW CAN PUBLIC-PRIVATE-ACADEMIC PARTNERSHIPS BE STRENGTHENED?

Room 300-301

Moderator: Isao Kamae, MD, DrPH, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan

Panelists: Allen Yu-Hung Lai, MD, MSc, MPA, PhD, Principal of Health Economics & Outcomes Research, IMS Health, Singapore; **Akio Onishi, PhD**, Professor, Graduate School of Public Policy, Tokyo, Japan; **Jörg Mahlich, PhD**, Health Economics, Janssen Pharmaceuticals KK, Tokyo, Japan

IP3: JOINT HTA: THE NEXT STEP FOR THE ASEAN ECONOMIC COMMUNITY? Room 325

Moderator: Gengshi Chen, MSc, Senior Analyst, Costello Medical Singapore Pte Ltd, Singapore

Panelists: Surachat Ngorsuraches, PhD, Associate Professor, Department of Pharmacy Practice, College of Pharmacy, South Dakota State University, Brookings, SD, USA; **W. Ken Redekop, PhD, MPH**, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

ECONOMIC OUTCOMES RESEARCH ISSUES

IP4: RISKY BUSINESS: DECISION MAKING IN HEALTH CARE WITH ECONOMIC MODELLING UNCERTAINTY Room 324

Moderator: Paul Scuffham, PhD, Professor of Health Economics, Population and Social Health Research, Griffith University, Gold Coast, Australia

Panelists: Hansoo Kim, MStat, Market Access Manager, Bristol-Myers Squibb Australia, Mulgrave, Australia; **Stephen Goodall, PhD, MSc**, Associate Professor, Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia; **Rosalie Viney, PhD**, Professor, Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: SUNDAY, 4 SEPTEMBER

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES

IP5: ESTIMATING COUNTRY-SPECIFIC EQ-5D-5L VALUE SETS USING A HYBRID REGRESSION MODEL: IS IT A GOOD IDEA FOR ASIA? Room 326

Moderator: Nan Luo, PhD, Associate Professor, National University of Singapore, Singapore

Panelists: Kim Rand-Hendriksen, PhD, CPsychol, Post-Doctoral Fellow, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway; Juan Manuel Ramos-Goñi, MSc, Research Scientist, The EuroQol Research Foundation, Rotterdam, The Netherlands; Mark Oppe, PhD, Senior Scientist, Executive Office, EuroQol Research Foundation, Rotterdam, The Netherlands

4:45PM-5:00PM **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I**

5:00PM-6:00PM **WORKSHOPS – SESSION I**

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W1: APPLYING HEALTH TECHNOLOGY ASSESSMENT TO PRECISION MEDICINE: EVALUATING NOVEL DIAGNOSTIC TESTS Room 324

Discussion Leaders: W. Ken Redekop, PhD, Associate Professor, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Hwee Lin Wee, PhD, Assistant Professor, Pharmacy, National University of Singapore, Singapore; Joanne Yoong, PhD, Senior Economist, University of Southern California and Associate Professor, National University of Singapore (NSU), Singapore

USE OF REAL WORLD DATA

W2: EVOLVING METHODS FOR STAGING PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN MATURE AND EMERGING MARKETS Summit 1

Discussion Leaders: David Thompson, PhD, Senior Vice President, Real World Evidence Consulting, inVentivHealth, Burlington, MA, USA; Jianwei Xuan, MD, PhD, Advisory Professor, School of Public Health, Fudan University, Shanghai, China; Linda Liong, BS, Project Director, Late Stage Operations, APAC, inVentiv Health, Singapore

W3: AN INTRODUCTION TO THE CASEMIX DATABASE IN MALAYSIA, INDONESIA, AND PHILIPPINES Room 300-301

Discussion Leaders: Syed Mohamed Aljunid, MD, MSc, PhD, Professor, Faculty of Public Health, Department of Health Policy and Management, Kuwait University, Kuwait City, Kuwait; Soraya Azmi, MD, MPH, Managing Director, Azmi Burhani Consulting, Petaling Jaya, Malaysia; Adrian Goh, MEd, Health Economist, Azmi Burhani Consulting, Petaling Jaya, Malaysia; Amrizal Muhd Nur, MD, MSc, PhD, Senior Research Fellow, Universiti Kebangsaan Malaysia, Cheras, Malaysia

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

W4: COMBINING TWO TYPES OF VALUATION DATA TO ESTIMATE HEALTH STATE UTILITIES: THE HYBRID REGRESSION MODEL Room 326

Discussion Leaders: Juan Manuel Ramos-Goñi, MSc, Research Scientist, The EuroQol Research Foundation, Rotterdam, The Netherlands; Mark Oppe, PhD, Senior Scientist, Executive Office, EuroQol Research Foundation, Rotterdam, The Netherlands; Nan Luo, PhD, Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Kim Rand-Hendriksen, PhD, CPsychol, Post-Doctoral Fellow, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway

W5: VALUE PROPOSITION DEVELOPMENT: COMMUNICATING VALUE IN THE PATIENTS' LANGUAGE Room 325

Discussion Leaders: Bruce Crawford, MA, MPH, Senior Principal, Real-World Evidence Solutions, Japan & APAC, IMS Japan K.K., Minato-ku, Tokyo, Japan; Keiko Wada, MA, Senior Consultant, Real-World Evidence Solutions, IMS Japan K.K., Minato-ku, Tokyo, Japan; Joe Caputo, BSc, Associate Director, ESSEC Institute of Health Economics and Management, ESSEC Asia-Pacific, Singapore; Jittrakul Leartsakulpanitch, PhD, Head, Market Access, Janssen Asia Pacific, Singapore

6:00PM-7:30PM **EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I Nicoll 1-3**

Reception sponsored by Quintiles



6:30PM-7:30PM **RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION I Nicoll 1-3**

7:30PM-9:00PM **ASIA CONSORTIUM RECEPTION Room 308-309**

All attendees welcome. Meet leaders from the Asia-Pacific region. Students and newcomers particularly encouraged to attend.

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: MONDAY, 5 SEPTEMBER

Monday

5

MONDAY, 5 SEPTEMBER

7:15AM-8:15AM **EDUCATIONAL SYMPOSIUM *Summit 1***

MANAGING HIGH-COST INNOVATIVE MEDICINES IN ASIA: WHAT ARE THE LATEST TRENDS AND REAL-WORLD PRACTICE?

Sponsored by TEVA



8:30AM-7:30PM **RESEARCH POSTER PRESENTATIONS – SESSION II *Nicoll 1-3***

8:30AM-9:30AM **RESEARCH PODIUM PRESENTATIONS – SESSION I**

(Abstracts are currently available on the <https://mysporsingapore.zerista.com> website, ISPOR Singapore mobile app, and abstracts PDF on the ISPOR website.)

CANCER OUTCOMES STUDIES ***Summit 1***

CA1 **TWO NEW CANCER-SPECIFIC MULTI-ATTRIBUTE UTILITY INSTRUMENTS: EORTC QLU-C10D AND FACT-8D**
8:30AM-8:45AM **King MT¹**, Norman R², Viney R³, Costa D¹, Brazier J⁴, Cella D⁵, Gamper E⁶, Kemmler G⁷, McTaggart-Cowan H⁸, Peacock S⁸, Pickard AS⁹, Rowen D⁴, Young TA⁴, ¹University of Sydney, Sydney, Australia, ²Curtin University, Perth, Australia, ³University of Technology Sydney, Sydney, Australia, ⁴University of Sheffield, Sheffield, UK, ⁵Northwestern University, Chicago, IL, USA, ⁶Medical University of Innsbruck, Innsbruck, Austria, ⁷Medical University of Innsbruck, Department of Psychiatry and Psychotherapy, Innsbruck, Austria, ⁸Canadian Centre for Applied Research in Cancer Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada, ⁹University of Illinois at Chicago, Chicago, IL, USA

CA2 **BREAST CANCER IN CHINA: ROOM FOR IMPROVED SCREENING**
8:45AM-9:00AM **Stankus AP¹**, Vietri J¹, Liu GG², ¹Kantar Health, Horsham, PA, USA, ²Peking University, Beijing, China

CA3 **THE QUALITY OF PHARMACOECONOMIC PUBLICATIONS IN BREAST CANCER PHARMACOTHERAPIES IN CHINA**
9:00AM-9:15AM **Ma F¹**, Cheng X², Zhou J¹, Aballéa S³, Toumi M⁴, ¹Creativ-Ceutical, Beijing, China, ²Creativ-Ceutical, Hong Kong, China, ³Creativ-Ceutical, Paris, France, ⁴Aix-Marseille University, Marseille, France

CA4 **GENDER-SPECIFIC PATTERNS OF PRODUCTIVITY LOSS IN COLORECTAL CANCER SURVIVORS IN A MULTI-ETHNIC ASIAN POPULATION**
9:15AM-9:30AM **Soon S¹**, Chia JW², Chew MH³, Tan WS³, Yang XY¹, Wee HL¹, ¹National University of Singapore, Singapore, ²National Cancer Centre Singapore, Singapore, ³Singapore General Hospital, Singapore

COST UTILITY AND QALY STUDIES ***Room 325***

CU1 **COST-UTILITY ANALYSIS OF HERPES ZOSTER VACCINE IN THAILAND**
8:30AM-8:45AM Taychakhoonavudh S¹, **Suranant N¹**, Issarasenee K¹, Laoprasertsuk C¹, Jiamton S², Chanyachailert P², Leeyaphan C², ¹Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand, ²Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

CU2 **FORECASTING LIFETIME HEALTH OUTCOMES AND COSTS OF TREATMENT FOR NON-ALCOHOLIC FATTY LIVER DISEASE**
8:45AM-9:00AM **Chongmelaxme B¹**, Phisalprapa P², Sawangjit R³, Dilokthornsakul P¹, Chaiyakunapruk N⁴, ¹Naresuan University, Phitsanulok, Thailand, ²Mahidol University, Bangkok, Thailand, ³Maharakham University, Muang, Thailand, ⁴Monash University Malaysia, Selangor, Malaysia

CU3 **LIFE EXPECTANCY, QUALITY-ADJUSTED LIFE YEARS, AND TOTAL LIFETIME COSTS FOR AUSTRALIAN PEOPLE WITH MULTIPLE SCLEROSIS**
9:00AM-9:15AM Palmer AJ, Taylor B, Van der Mei I, Si L, **Ahmad H**, University of Tasmania, Hobart, Australia

CU4 **DEVELOPMENT OF AN ALCOHOL POLICY MODEL THAT PREDICTS LIFE YEARS, QALYS, AND HEALTH CARE COSTS ACCOUNTING FOR ALCOHOL USE DISORDER IDENTIFICATION TEST**
9:15AM-9:30AM **Lewsey J**, Leelahavarong P, Briggs A, University of Glasgow, Glasgow, UK

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: MONDAY, 5 SEPTEMBER

HEALTH CARE EXPENDITURE AND PRICING STUDIES *Room 300-301*

- HC1** **IMPACT OF ADOPTION OF A NEW DRUG ON THE TRENDS IN UTILIZATION PATTERNS CHANGES AND PHARMACEUTICAL EXPENDITURE- AN EXAMPLE OF URATE-LOWERING THERAPY**
8:30AM-8:45AM **Peng Y¹**, Hsu C², ¹Kaohsiung Medical University, Kaohsiung, Taiwan, ²Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
- HC2** **MULTIMORBIDITY AND HEALTH CARE SERVICE UTILIZATION IN THE AUSTRALIAN WORKFORCE: FINDINGS FROM THE NATIONAL HEALTH SURVEY**
8:45AM-9:00AM **Wang L¹**, Palmer AJ¹, Cocker F², Sanderson K¹, ¹Menzies Institute for Medical Research, Hobart, Australia, ²Monash Centre for Occupational and Environmental Health (MonCOEH), Melbourne, Australia
- HC3** **COMPARISON OF MEDICAL COSTS, HEALTH CARE UTILIZATION, AND HEALTH OUTCOMES BETWEEN THE ELDERLY WITH AND WITHOUT DISABILITIES IN KOREA**
9:00AM-9:15AM **Kim HJ¹**, Lee S¹, Kim JH¹, Ho SH¹, Lee SJ², Lee B², ¹Korea National Rehabilitation Center, National Rehabilitation Research Institute, Seoul, South Korea, ²Korea National Rehabilitation Center, National Rehabilitation Hospital, Seoul, South Korea
- HC4** **DERIVATION AND EXTERNAL VALIDATION OF AN EARLY READMISSION RISK PREDICTION MODEL**
9:15AM-9:30AM **Dorajoo SR¹**, See V¹, Chan CT¹, Tan ZY², Koomanan N³, Ong TT⁴, Razak SM⁴, Yap CW¹, Chan A¹, ¹National University of Singapore, Singapore, ²Khoo Teck Puat Hospital, Singapore, ³Singapore General Hospital, Singapore, ⁴Temasek Polytechnic, Singapore

INFECTIOUS DISEASE STUDIES *Room 324*

- IN1** **BUSINESS INTELLIGENCE FOR DETECTING POSSIBLE SURGICAL SITE INFECTIONS FROM GALLBLADDER SURGERY (CHOL) AND COLON SURGERY (COLO) IN RAMATHIBODI HOSPITAL, THAILAND**
8:30AM-8:45AM **Piebpien P**, Vajiratanakorn S, Somsakul S, Muntajit T, Sukkra S, Leelaudomlipi S, Samankatiwat P, Malathum K, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- IN2** **AN UPDATED COST-EFFECTIVENESS ANALYSIS OF SYNFLORIX UNIVERSAL MASS VACCINATION IMPLEMENTATION IN NEW ZEALAND**
8:45AM-9:00AM **Varghese L¹**, Talbot L², Govender A², Mungall B¹, ¹GlaxoSmithKline Vaccines, Singapore, ²GlaxoSmithKline Vaccines, Auckland, New Zealand
- IN3** **EFFECTS OF HBSAG POSITIVITY DURING PREGNANCY ON ADVERSE MATERNAL OUTCOMES: A RETROSPECTIVE DATABASE ANALYSIS**
9:00AM-9:15AM **Tan J¹**, Sun X², ¹School of West China Public Health, Sichuan University, Chengdu, China, ²West China Hospital of Sichuan University, Chengdu, China
- IN4** **THE SALE OF ANTIBIOTICS WITHOUT PRESCRIPTION IN RETAIL PHARMACIES: A CROSS-SECTIONAL SURVEY IN THREE CITIES OF CHINA**
9:15AM-9:30AM **Chang J**, Ye D, Fang Y, Xi'an Jiaotong University, Xi'an, China

RESEARCH ON METHODS STUDIES *Room 326*

- RM1** **NETWORK META-ANALYSIS OF RANDOMIZED TRIALS TO COMPARE THE EFFICACY OF NSAIDS, STATINS AND VITAMINS IN ALZHEIMER'S DISEASE**
8:30AM-8:45AM **Pandey R¹**, Jha D², Pandey P¹, Shah V³, ¹SIRO Clinpharm Pvt Ltd, Thane, India, ²Birla Institute of Technology, Ranchi, India, ³SIRO Clinpharm Pvt Ltd, Maharashtra, India
- RM2** **DEVELOPMENT, VALIDATION, AND PILOT TESTING OF METABOLIC SYNDROME QUALITY OF LIFE QUESTIONNAIRE (TAPMETSQOL)**
8:45AM-9:00AM **Kethireddy K**, Talla V, Pasam Ns, Koutika N, Hunsur Nagendra V, Talla Padmavathi College of Pharmacy, Warangal, India
- RM3** **COMPARISON OF CAREGIVER-RATED 3-LEVEL EUROQOL-5D (EQ-5D-3L) AND HEALTH UTILITIES INDEX MARK 3 (HUI3) IN PATIENTS WITH DEMENTIA IN SINGAPORE**
9:00AM-9:15AM **Wang VW¹**, Kandiah N², Lin X², Wee HL¹, ¹National University of Singapore, Singapore, ²National Neuroscience Institute, Singapore
- RM4** **RELIABILITY AND VALIDITY OF THE HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) IN PATIENTS WITH SPONDYLOARTHRITIS**
9:15AM-9:30AM **Kwan YH¹**, Yong ST², Fong W², Lui NL², Malhotra R¹, Thumboo J³, Ostbye T¹, ¹Duke-NUS Medical School, Singapore, ²Singapore General Hospital, Singapore, ³Singhealth, Singapore

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: MONDAY, 5 SEPTEMBER

9:45AM-10:45AM RESEARCH PODIUM PRESENTATIONS – SESSION II

(Abstracts are currently available on the <https://mysporsingapore.zerista.com> website, ISPOR Singapore mobile app, and abstracts PDF on the ISPOR website.)

COST-EFFECTIVENESS STUDIES **Room 325**

CE1 CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF NOVEL ORAL ANTICOAGULANTS INCORPORATING REAL-WORLD ELDERLY PATIENTS WITH ATRIAL FIBRILLATION

9:45AM-10:00AM

Zhao YJ¹, Lin L¹, Zhou HJ¹, Khoo AL¹, Tan KT², Chew AP³, Foo CG⁴, Oh CT⁵, Lim WS³, Lim BP¹, ¹Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore, ²Department of Pharmacy, Tan Tock Seng Hospital, Singapore, ³Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore, ⁴Department of Cardiology, Tan Tock Seng Hospital, Singapore, ⁵Department of Neurology, National Neuroscience Institute, Singapore

CE2 COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN TAIWAN

10:00AM-10:15AM

Zou D¹, Kendall R¹, Lin Q², Huang Y², Tieng J³, Tseng J³, Sajosi P⁴, ¹ICON plc, Vancouver, BC, Canada, ²Kantar Health, Taipei, Taiwan, ³Takeda Pharmaceuticals Taiwan, Taipei, Taiwan, ⁴Takeda Pharmaceuticals International AG, Zurich, Switzerland

CE3 COST-EFFECTIVENESS OF CYP2C19*2 GENOTYPE GUIDED SELECTION OF CLOPIDOGREL OR TICAGRELOR IN HONG KONG CHINESE PATIENTS WITH ACUTE CORONARY SYNDROME

10:15AM-10:30AM

Lee VW¹, **Wang Y**¹, Liew D², Yan BP¹, ¹The Chinese University of Hong Kong, Shatin, Hong Kong, China, ²Monash University, Melbourne, Australia

CE4 THE MULTIDISCIPLINARY RISK ASSESSMENT AND MANAGEMENT PROGRAM – DIABETES MELLITUS (RAMP-DM) WAS COST-EFFECTIVE FOR MANAGING PATIENTS WITH DIABETES MELLITUS

10:30AM-10:45AM

Jiao F, Lam CL, Fung CS, Wan EY, Wong CK, McGhee S, The University of Hong Kong, Hong Kong, China

CARDIOVASCULAR OUTCOMES STUDIES **Summit 1**

CV1 CAN ACUTE PHASE CLINICAL OUTCOMES PREDICT HEALTH-RELATED QUALITY OF LIFE AFTER STROKE?

9:45AM-10:00AM

Yeoh YS, Luo N, Koh GC, National University of Singapore, Singapore

CV2 QUALITY OF LIFE OF STROKE SURVIVORS AND THEIR INFORMAL CAREGIVERS: A PROSPECTIVE STUDY

10:00AM-10:15AM

Chuluunbaatar E, National Yang Ming University, Ulaanbaatar, Mongolia

CV3 ONGOING ANALYSIS OF CLINICAL AND ECONOMIC OUTCOMES OF JAPANESE PATIENTS WITH CORONARY HEART DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

10:15AM-10:30AM

Martinsen BJ, Cardiovascular Systems, Inc., St. Paul, MN, USA

CV4 ADOPTION OF INNOVATIVE TECHNOLOGIES AND SUBSTITUTION EFFECTS: COMPUTED TOMOGRAPHIC CORONARY ANGIOGRAPHY IN AUSTRALIA

10:30AM-10:45AM

Gericke CA¹, Mohasseb I², Duncan E³, Younger J², ¹University of Queensland, Brisbane, Australia, ²Royal Brisbane and Women's Hospital, Brisbane, Australia, ³Queensland University of Technology, Brisbane, Australia

DIABETES OUTCOMES STUDIES **Room 300-301**

DB1 DPP-4 INHIBITORS AND CARDIOVASCULAR EVENTS IN TYPE 2 DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE – A NATIONWIDE COHORT STUDY

9:45AM-10:00AM

Huang T, Hsiao F, Shen L, National Taiwan University, Taipei, Taiwan

DB2 HBA1C VARIABILITY PREDICTS SHORT-TERM RISK OF ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES

10:00AM-10:15AM

Dorajoo SR¹, Ng SL¹, Goh HF², Lim SC², Yap CW¹, Chan A¹, Lee J¹, ¹National University of Singapore, Singapore, ²Khoo Teck Puat Hospital, Singapore

DB3 INCREMENTAL COST-EFFECTIVENESS OF ALGORITHM-DRIVEN GENETIC TESTING VERSUS NO TESTING FOR MATURITY ONSET DIABETES OF THE YOUNG (MODY) IN SINGAPORE

10:15AM-10:30AM

Nguyen HV¹, **Finkelstein EA**¹, Mital S¹, Gardner DS², ¹Duke NUS Medical School, Singapore, ²Singapore General Hospital, Singapore

DB4 RELATIONSHIP BETWEEN INSULIN ADHERENCE AND HEALTH CARE RESOURCE UTILIZATION AMONG TYPE 2 DIABETES PATIENTS IN CHINA

10:30AM-10:45AM

He X¹, **Wang K**², Shen L², Wu J¹, ¹Tianjin University, Tianjin, China, ²Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, China

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: MONDAY, 5 SEPTEMBER

DISEASE MANAGEMENT STUDIES *Room 324*

- DM1** **COMMUNITY RESIDENTS' KNOWLEDGE AND ATTITUDES TOWARDS ANTIBIOTICS IN PENANG, MALAYSIA: A CROSS-SECTIONAL STUDY**
9:45AM-10:00AM
Irawati L¹, Hassali MA¹, Saleem F¹, Alrasheedy AA², ¹Universiti Sains Malaysia, Penang, Malaysia, ²Qassim University, Qassim, Saudi Arabia
- DM2** **PATIENT CHARACTERISTICS AND TREATMENT PATTERNS OF VENOUS THROMBOEMBOLISM (VTE) AMONG HOSPITALIZED PATIENTS IN CHINA: AN ANALYSIS OF ELECTRONIC MEDICAL RECORD DATA**
10:00AM-10:15AM
Wu C¹, Chen H², Xie J³, Han S⁴, Horblyuk R⁵, **Wang PE⁶**, Liu L⁷, Lu J⁸, Song H⁴, Du EX⁹, Wu EQ⁹, ¹Peking University Shenzhen Hospital, Shenzhen, China, ²Peking University People's Hospital, Beijing, China, ³Analysis Group, Inc., New York, NY, USA, ⁴Analysis Group, Inc., Beijing, China, ⁵Pfizer, Inc., New York, NY, USA, ⁶Bristol-Myers Squibb, Princeton, NJ, USA, ⁷Merck, New York, NY, USA, ⁸Pfizer Investment Co., Ltd., Beijing, China, ⁹Analysis Group, Inc., Boston, MA, USA
- DM3** **ADHERENCE TO OSTEOPOROSIS DRUGS AND CLINICAL OUTCOMES AMONG OSTEOPOROSIS PATIENTS WITH DIFFERENT RISK PROFILES**
10:15AM-10:30AM
Huang S¹, Wang C¹, Lu W², Hsiao F¹, ¹School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, ²National Taiwan University, Taipei, Taiwan
- DM4** **COMPARATIVE EFFECTIVENESS ANALYSIS FOR SMOKING CESSATION MEDICATIONS ON SMOKING CESSATION AND RELAPSES AMONG ELDERLY SMOKERS**
10:30AM-10:45AM
Yuan Y¹, Chang P², Lo P³, Chang H³, Su P⁴, Hsueh K⁵, Tsai Y³, **Lan T⁶**, ¹Cheng-Hsin General Hospital, Taipei, Taiwan, ²Department of Medicine, Stanford University School of Medicine, California, CA, USA, ³Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan, ⁴Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan, ⁵Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁶Center for Geriatrics and Gerontology Taichung Veterans General Hospital, Taichung, Taiwan

HEALTH TECHNOLOGY ASSESSMENT STUDIES *Room 326*

- HT1** **WHAT DO HTAS LOOK LIKE AROUND THE WORLD? A COMPARISON OF SOUTH KOREAN AND BRITISH HTA AGENCIES**
9:45AM-10:00AM
Versoza L, Adler B, Blumenthal J, Chang R, Ho Y, Rubinstein ER, Rubinstein JL, Sliman RC, Smith MZ, Context Matters Inc., New York, NY, USA
- HT2** **A HEALTH TECHNOLOGY ASSESSMENT OF HOME-BASED HAEMODIALYSIS IN ESRD PATIENTS**
10:00AM-10:15AM
Chahar A, Sharma M, Sharma J, WHO Collaborating Centre for Priority Medical Devices & Health Technology Policy, NHRSC, New Delhi, India
- HT3** **DIFFERENTIAL PATTERNS OF PERSISTENT OPIOID USE IN PATIENTS WITH CANCER AND NON-CANCER PAIN**
10:15AM-10:30AM
Sani AR¹, Zin CS¹, Noor ZM¹, Mohamed AH¹, Nissen LM², ¹International Islamic University Malaysia, Kuantan, Malaysia, ²Queensland University of Technology, Kelvin Grove, Australia
- HT4** **HUMANISTIC AND ECONOMIC OUTCOMES OF PHARMACIST-PROVIDED MEDICATION REVIEWS IN THE ELDERLY: A SYSTEMATIC REVIEW AND META-ANALYSIS**
10:30AM-10:45AM
Loh ZW¹, **Cheon HH²**, Wee HL¹, ¹National University of Singapore, Singapore, ²Singapore General Hospital, Singapore

10:45AM-11:15AM **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II *Nicoll 1-3***

11:15AM-12:45PM **WELCOME & SECOND PLENARY SESSION *Summit 1***

WELCOME FROM ISPOR ASIA CONSORTIUM EXECUTIVE COMMITTEE CHAIR

Isao Kamae, MD, DrPH, 2016-2018 ISPOR Asia Consortium Executive Committee Chair and Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan



Kamae

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: MONDAY, 5 SEPTEMBER

SECOND PLENARY SESSION: HARNESSING THE POWER OF BIG DATA TO MAKE BETTER HEALTH CARE DECISIONS IN THE ASIA-PACIFIC REGION

Health care in Asia is embracing the global big data movement since big data has tremendous potential to add value in all health care settings. This session will discuss key ways in which big data can deliver value through clinical and financial benefits to health systems, such as aiding personalized medicine and streamlining health resource planning. It will also discuss current challenges and opportunities for utilizing big data to improve health care decision making in the Asia-Pacific region while addressing multi-stakeholder perspectives and regional considerations.

Moderator: **Louisa Jorm, PhD**, Professor & Director, Centre for Big Data Research in Health, University of New South Wales (UNSW), Sydney, Australia

Speakers:

Christopher Chute, MD, DrPH, Bloomberg Distinguished Professor of Health Informatics, Professor of Medicine, Public Health, and Nursing, and Chief Health Research Information Officer, Johns Hopkins Medicine, Johns Hopkins University, Baltimore, MD, USA

Trish Williams, PhD, Professor & Chair of Digital Health Technologies, Flinders University, Adelaide, Australia

Yoke Sin Chong, PhD, Chief Executive Officer, Integrated Health Information Systems Pte Ltd, Singapore



Jorm



Chute



Williams



Chong

12:45PM-3:45PM **LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II** *Nicoll 1-3*

1:15PM-2:15PM **EDUCATIONAL SYMPOSIUM** *Summit 1*

HOW REAL-WORLD EVIDENCE (RWE) CAN ENABLE PHARMA TO PARTNER IN HEALTH CARE DELIVERY

Sponsored by IMS Health

imshealth™

2:30PM-3:30PM **EDUCATIONAL SYMPOSIUM** *Summit 1*

PRICING DEVELOPMENTS IN THE ASIA PACIFIC – DOES COMPARATOR-REFERENCED PRICING HAVE A FUTURE?

Sponsored by Optum

OPTUM™

3:45PM-4:45PM **ISSUE PANELS – SESSION II**

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP6: HOW DO CULTURE, VALUES, AND INSTITUTIONAL CONTEXT SHAPE THE METHODS AND USE OF ECONOMIC EVALUATION? *Room 324*

Moderator: **Michael Drummond, MCom, DPhil**, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

Panelists: **Takashi Fukuda, PhD**, Director, National Institute of Public Health, Wako, Japan; **Yen-Huei (Tony) Tarn, PhD, MS**, Associate Professor, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan; **Paul Scuffham, PhD**, Professor of Health Economics, Population and Social Health Research, Griffith University, Gold Coast, Australia

IP7: THE ROLE OF HTA UNDER THE UNIVERSAL HEALTH COVERAGE SYSTEM: HOW WILL IT WORK FOR ASIA? *Room 326*

Moderator: **Allen Yu-Hung Lai, MD, MSc, MPA, PhD**, Principal of Health Economics & Outcomes Research, IMS Health, Singapore

Panelists: **Bruno Rossi, BA**, Advisor, Bayer Yakuhin, Ltd., Osaka, Japan; **Bin Chia Wu, PhD**, Head, Economic Modeling, Ministry of Health Singapore, Singapore; **W. Ken Redekop, PhD, MPH**, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

IP8: COULD MULTIPLE-CRITERIA DECISION ANALYSIS HELP DECISION MAKERS FOR REIMBURSEMENT OF IMMUNO-ONCOLOGY MEDICINES? *Room 300-301*

Moderator: **Tan Seng Chuen, BPharm (Hons), MSc**, Director, Market Access (Oncology), MSD, Singapore

Panelists: **Daniel Chan, DrMBBS**, Specialist in Medical Oncology, Singapore Oncology Consultants, Singapore; **James Pellissier, PhD**, Executive Director, Predictive & Economic Modeling, Merck Research Laboratories, Merck & Co., Inc., North Wales, PA, USA; **Eui-Kyung Lee, PhD**, Professor, Pharmaceutical Policy & Outcomes Research, School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: MONDAY, 5 SEPTEMBER

IP9: PREDICTING FUTURE EVIDENCE: RISK-SHARING AGREEMENTS, MANAGED ENTRY SCHEMES, OR SOMETHING ELSE?

Summit 1

Moderator: William Montgomery, BPharm, Principal Research Scientist, Eli Lilly Australia Pty Ltd., Sydney, Australia

Panelists: Andrew Mitchell, MMedSci, Strategic Adviser, Evaluation, Department of Health, Canberra, Australia; Rosalie Viney, PhD, Professor, Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia; David Grainger, BSc, Director, Global Public Policy, Eli Lilly and Company, Sydney, Australia

CLINICAL OUTCOMES RESEARCH ISSUES

IP10: CLINICAL TRIALS FOR REGULATORY AND REIMBURSEMENT NEEDS: DOES ONE SHOE FIT ALL? Room 325

Moderator: Hansoo Kim, MSc, Market Access Manager, Bristol-Myers Squibb Australia, Mulgrave, Australia

Panelists: Danny Liew, PhD, Professor, Monash University, Melbourne, Australia; Stephen Goodall, PhD, MSc, Associate Professor, Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia; Alissa Brown, MPH, Head of Market Access, Sanofi Australia, Macquarie Park, Australia

4:45PM-5:00PM

BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II Nicoll 1-3

5:00PM-6:00PM

WORKSHOPS – SESSION II

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W6: ADAPTING PHARMACOECONOMIC DATA OF ANALYSES FROM OVERSEAS FOR USE IN DECISIONS IN MIDDLE INCOME COUNTRIES Room 326

Discussion Leaders: Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Bong-Min Yang, PhD, Professor, School of Public Health and Executive Director, Institute of Health and Environment, Seoul National University, Seoul, South Korea; Jasmine Pwu, PhD, Senior Investigator, Health Data Research Centre, National Taiwan University, Taipei, Taiwan; Nathorn Chaiyakunapruk, PhD, Professor of Health Economics, School of Pharmacy, Monash University Malaysia, Selangor, Malaysia

USE OF REAL WORLD DATA

W7: SHARING REAL-WORLD DATA EXPERIENCES OF USING TAIWAN'S NATIONAL HEALTH INSURANCE RESEARCH DATABASE Room 300-301

Discussion Leaders: Ming-Hui Tai, MS, MHPA, PhD, Lead Outcomes Research Analyst, Pharmerit International, Bethesda, MD, USA; Chung-Hsuen Wu, PhD, Assistant Professor, Department of Clinical Pharmacy, Taipei Medical University, Taipei City, Taiwan; Fang-Ju Lin, PhD, Assistant Professor, Graduate Institute of Clinical Pharmacy, National Taiwan University, Taipei, Taiwan; Yu-Chen Yeh, MS, RPh, Senior Clinical Outcomes Scientist, Pharmerit International, Newton, MA, USA

ECONOMIC OUTCOMES RESEARCH

W8: APPLIED EARLY ECONOMIC MODELLING FOR COMBINATION THERAPIES IN ONCOLOGY: NOVEL VALUE-BASED PRICING APPROACH Summit 1

Discussion Leaders: Cyrus A. Chowdhury, CEO & Managing Director, CBPartners, New York, NY, USA; Meghan Gallagher, Director, Global Health Economics and Outcomes Research, Oncology, Sanofi, Cambridge, MA, USA; Kateryna Onishchenko, PhD, Health Economist, CBPartners, London, UK

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

W9: INCORPORATING FINANCIAL INCENTIVES AND PATIENT PREFERENCES IN THE DESIGN OF CANCER SCREENING PROGRAMMES Room 324

Discussion Leaders: W. Ken Redekop, PhD, MPH, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Hwee Lin Wee, PhD, Assistant Professor, Pharmacy, National University of Singapore, Singapore; Joanne Yoong, PhD, Senior Economist, University of Southern California and Associate Professor, National University of Singapore, Singapore

W10: TAKING PATIENT PREFERENCES INTO CONSIDERATION IN THE PATIENT-CENTERED HEALTH CARE SYSTEM Room 325

Discussion Leaders: Jianwei Xuan, MD, PhD, Director, Health Economic Research Institute, Sun Yat-sen University, Guangzhou, China; Boxiong Tang, MD, PhD, Senior Director, Global Health Economics and Outcomes Research, Teva Pharmaceutical, Frazer, PA, USA; Yi Han, PhD, MBA, Executive Vice President, Market Access and HEOR, Cello Health, Yardley, PA, USA

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: MONDAY, 5 SEPTEMBER & TUESDAY, 6 SEPTEMBER

6:00PM-7:30PM **EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II *Nicoll 1-3***

Reception Sponsored by Taylor & Francis



Taylor & Francis Group
an informa business

6:30PM-7:30PM **RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION II *Nicoll 1-3***

Tuesday

6 TUESDAY, 6 SEPTEMBER

7:15AM-8:15AM **EDUCATIONAL SYMPOSIUM *Summit 1***

HEALTH ECONOMIC ASSESSMENT ON TARGET THERAPY ON COLORECTAL CANCER TREATMENT

Sponsored by Merck Serono

8:30AM-3:00PM **RESEARCH POSTER PRESENTATIONS – SESSION III *Nicoll 1-3***

8:30AM-9:30AM **ISPOR FORUMS – SESSION I**

F1: HEALTH TECHNOLOGY ASSESSMENTS IN UNIVERSAL HEALTH COVERAGE *Room 300-301*

Presented by the ISPOR Asia Consortium Health Technology Assessment Agencies, Health Care Policymakers & Payers Committee

Moderator: Jitendar Sharma, PhD, CEO, Andhra Med Tech Zone (AMTZ) and Head, Division of Healthcare Technology & Director, WHO Collaborating Center for Priority Medical Devices, National Health Systems Resource Centre, Ministry of Health & Family Welfare, New Delhi, India

Speakers: Kun Zhao, MD, PhD, Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center, National Health and Family Planning Commission (NHFPC), Beijing, China; Joanne Yoong, PhD, Senior Economist, University of Southern California and Associate Professor, National University of Singapore, Singapore; Surachat Ngorsuraches, PhD, Associate Professor, College of Pharmacy, South Dakota State University, Brookings, South Dakota, USA and Former Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand

F2: INTEGRATING EVIDENCE-BASED AND COST-EFFECTIVE COMPLEMENTARY AND ALTERNATIVE MEDICINE INTO THE HEALTH CARE SYSTEMS IN ASIA *Room 324*

Presented by the ISPOR Asia Consortium Complementary and Alternative Medicine (CAM) Working Group

Moderator: Namkwen Kim, KMD, MPH, PhD, Professor, Pusan National University School of Korean Medicine and Director, Monitoring Center for Korean Medicine and Western Collaboration, Pusan National University Korean Medicine, Yangsan, South Korea

Speakers: Ming Hu, PhD, Professor & Director, Pharmaceutical Policy & Pharmaceconomics Research Center, West China School of Pharmacy, Sichuan University, Chengdu, China; Hwee Ling Koh, PhD, Associate Professor, Department of Pharmacy, National University of Singapore, Singapore; Wendy Wong, PhD, Assistant Professor, Hong Kong Institute of Integrative Medicine, Assistant Professor, School of Chinese Medicine and Deputy Chief Chinese Medicine Practitioner, Integrative Medical Centre, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Donghyo Lee, DKM, PhD, Assistant Professor, College of Korean Medicine, Woosuk University, Jeonju, Jeonbuk, South Korea

F3: BIG DATA IN ASIA-PACIFIC – A VALUABLE RESOURCE FOR BETTER HEALTH CARE DECISIONS: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN, SINGAPORE, SOUTH KOREA, AND TAIWAN *Summit 1*

Presented by the ISPOR Asia Consortium

Moderator: Libby Roughead, PhD, Director & Research Professor, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, SA, Australia

Speakers: Bruce Crawford, MA, MPH, Senior Principal, Real-World Evidence Solutions, Japan & APAC, IMS Japan K.K., Minato-ku, Tokyo, Japan; Hwee Lin Wee, PhD, Assistant Professor, Pharmacy, National University of Singapore, Singapore; SeungJin Bae, ScD, Associate Professor, Pharmacoeconomics and Outcomes Research, Ewha Women's University, Seoul, South Korea; Chee-Jen Chang, PhD, MS, Director, Clinical Informatics and Medical Statistics Research Center and Professor, Graduate Institute of Clinical Medical Sciences, Chang Gung University, TaoYuan, Taiwan

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: TUESDAY, 6 SEPTEMBER

F4: VALUE IN HEALTH REGIONAL ISSUES: GUIDANCE ON WRITING GOOD SCIENTIFIC MANUSCRIPTS FOR PUBLICATION

Room 326

Presented by the Value in Health Regional Issues (ViHRI) Editorial Board (Asia)

Moderator: Bong-Min Yang, PhD, Professor, School of Public Health and Executive Director, Institute of Health and Environment, Seoul National University, Seoul, South Korea

Speakers: Nathorn Chaikunapruk, PharmD, PhD, Professor of Health Economics, School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; Jianfei (Jeff) Guo, PhD, RPh, Professor, University of Cincinnati Health Academic Center, Cincinnati, OH, USA; Kenneth K. C. Lee, MPhil, PhD, Professor, School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia; Shu Chuen Li, PhD, Professor, School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, Australia

F5: PHARMACOECONOMIC GUIDELINES IN CHINA, INDIA, INDONESIA, MALAYSIA, AND THAILAND Room 325

Presented by the ISPOR Regional Chapters in China, India, Indonesia, and Malaysia

Moderator: JiuHong Wu, PhD, PharmD, Professor, The 306th Hospital of PLA, Beijing, China

Speakers: Mahendra Kumar Rai, MPharm, Group Leader & SME, HEOR & Real-World Evidence, Market Access & HEOR, Tata Consultancy Services, Mumbai, India; Amad Fuad Afdhal, PhD, Director, Center for Socio-Economic Studies in Pharmacy, Cirende, Indonesia; Syed Aljunid, MD, PhD, Professor, International Casemix and Clinical Coding Centre, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia; Sitaporn Youngkong, PhD, Lecturer, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand

9:45AM-10:45AM ISSUE PANELS – SESSION III

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP11: HOW CAN RISK-SHARING AGREEMENTS IN KOREA BE IMPROVED? Room 300-301

Moderator: Jae-Hyun Lee, PhD, MS, Professor, School of Pharmacy, SKKU University and Korea Regulatory Affairs Professionals Center, Seoul, South Korea

Panelists: Hyelin Kim, PhD, Professor, Department of Pharmaceutical Sciences, Sahmyook University, Seoul, South Korea; David Grainger, BSc, Director, Global Public Policy, Eli Lilly and Company, Sydney, Australia; Kevin Haninger, PhD, Associate Vice President, International Health Policy, PhRMA, Washington, DC, USA; Nam-Sun Choi, Deputy Manager, Department of Insurance Benefits, National Health Insurance Service (NHIS), Wonju, Korea

IP12: HOW CAN WE EMPOWER THE PATIENT VOICE IN HEALTH CARE DECISION MAKING AT THE POLICY LEVEL?

Room 324

Moderator: Joerg Klug, MA, MBA, Director, Market Access, Janssen Asia Pacific, Kowloon, Hong Kong

Panelists: Eui-Kyung Lee, PhD, Professor, Pharmaceutical Policy & Outcomes Research, School of Pharmacy, Sungkyunkwan University, Suwon, South Korea; Chih-Liang Yang, PhD, President, TAPO (Taiwan Alliance of Patients Organizations) and Former Minister of Health, Republic of China, Taiwan; Richard Vines, Chairman, Rare Cancers Australia, Bowral, Australia

IP13: WHAT IS THE OPTIMAL APPROACH TO CONFIGURING THE BURDEN OF PROOF DURING THE COST-CONTAINMENT ERA?

Summit 1

Moderator: Christoph Glaetzer, Dipl. Kfm, Vice President, Strategic Marketing and Market Access, Janssen Asia Pacific, Singapore

Panelists: Bor-Sheng Ko, MD, PhD, Assistant Professor, BMT Unit and Hematology Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Jeonghoon Ahn, PhD, Associate Professor, Department of Health Convergence, Ewha Woman University, Seoul, South Korea

IP14: HOW SHOULD WE ADDRESS THE SPECIFICITIES OF EVALUATING MEDICAL DEVICES? Room 326

Moderator: Allen Yu-Hung Lai, MD, MSc, MPA, PhD, Principal of Health Economics & Outcomes Research, IMS Health, Singapore

Panelists: Chunyue Yin, MD, PhD, MBA, Manager, Health Economics & Market Access, Johnson & Johnson Medical Asia-Pacific, Singapore; Laurent Metz, MD, PhD, Director, Health Economics Market Access & Clinical Research, MD&D Asia Pacific, Johnson & Johnson Medical Asia Pacific, Singapore

ECONOMIC OUTCOMES RESEARCH ISSUES

IP15: SHOULD PRODUCTIVITY LOSSES DUE TO ILLNESS BE CONSIDERED IN HEALTH ECONOMIC EVALUATIONS? Room 325

Moderator: Craig Brooks-Rooney, MA, Head, Asia-Pacific, Costello Medical Singapore Pte Ltd., Singapore

Panelists: Dominique Milea, PharmD, PhD, Director, Health Economics & Epidemiology Asia, Lundbeck Singapore Pte. Ltd., Singapore; W. Ken Redekop, PhD, MPH, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Hwee Lin Wee, PhD, Assistant Professor, Pharmacy, National University of Singapore, Singapore

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: TUESDAY, 6 SEPTEMBER

10:45AM-11:00AM **BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – III Nicoll 1-3**

11:00AM-12:45PM **WELCOME & THIRD PLENARY SESSION Summit 1**

WELCOME FROM ISPOR ASIA CONSORTIUM EXECUTIVE COMMITTEE CHAIR

Isao Kamae, MD, DrPH, 2016-2018 ISPOR Asia Consortium Executive Committee Chair and Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan



Kamae

ISPOR DISTINGUISHED SERVICE AWARDS

Presented by: Lou Garrison, PhD, 2016-2017 ISPOR President

AWARDEES:

Wai Keung Chui, PhD, ISPOR 7th Asia-Pacific Conference Program Committee Co-Chair, and Associate Professor, Department of Pharmacy, National University of Singapore, Singapore

Syed Aljunid, MD, PhD, ISPOR 7th Asia-Pacific Conference Program Committee Co-Chair, and Professor, Health Economics and Public Health Medicine & Head, International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia

Ahmad Fuad Afdhal, PhD, ISPOR 7th Asia-Pacific Conference Program Committee Co-Chair, and Director, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia

Kun Zhao, MD, PhD, ISPOR Asia Consortium HTAnetAsia 2014-2016 Chair, and Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center, National Health and Family Planning Commission (NHFP), Beijing, China



Garrison

ISPOR VALUE IN HEALTH REGIONAL ISSUES (ASIA) EXCELLENT ARTICLE AWARD

Presented by: Bong-Min Yang, PhD, ISPOR Value in Health Regional Issues Co-Editor-in-Chief (Asia)

AWARDEE: Fei-Li Zhao, PhD, Senior Research Fellow, Centre for Health Economics Research and Evaluation (CHERE), University of Technology Sydney, Sydney, Australia



Zhao

THIRD PLENARY SESSION: UNIVERSAL HEALTH COVERAGE – THE AFFORDABLE DREAM IN ASEAN: EXPERIENCES AND LESSONS LEARNED

The vast diversity in the historical, socio-economic, cultural, and political spheres has contributed to highly divergent health statuses and health systems across countries of the Association of Southeast Asian Nations (ASEAN). With increasing educational levels and affluence, ageing populations, availability of new health technology, and growing consciousness of human rights in this region, the demand for universal health coverage (UHC) of affordable and good quality health services is increasing. While a few countries in ASEAN, such as Singapore and Thailand, have already achieved UHC, others are moving towards it. This session will discuss the current situation, challenges, and opportunities of UHC, with the aim of sharing experiences and supporting each other in the joint pursuit of UHC in ASEAN.

Moderator: Ahmad Fuad Afdhal, PhD, Director, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia

Speakers:

Netnapis Suchonwanich, Former Deputy Secretary General, National Health Security Office (NHSO), Bangkok, Thailand

Syed Aljunid, MD, PhD, Professor, Health Economics and Public Health Medicine & Head, International Centre for Casemix and Clinical Coding,

Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia

Kun Zhao, MD, PhD, Professor & Director, Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center, National Health and Family Planning Commission (NHFP), Beijing, China

Graham Harrison, PhD, World Health Organization Representative to Malaysia, Brunei Darussalam and Singapore, World Health Organization (WHO), Kuala Lumpur, Malaysia



Afdhal



Suchonwanich



Aljunid



Zhao



Harrison

ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: TUESDAY, 6 SEPTEMBER

12:45PM-1:00PM **RESEARCH AWARDS PRESENTATION AND CONFERENCE REMARKS Summit 1**

Moderator: Isao Kamae, MD, DrPH, 2016-2018 ISPOR Asia Consortium Executive Committee Chair and Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan



Kamae

ISPOR BEST PODIUM PRESENTATION AWARDS

Presented by: Kenneth KC Lee, JP, MPhil, PhD Reg Pharm (HK), Professor of Pharmacy & Health, School of Pharmacy, Monash University, Selangor, Malaysia



Lee

ISPOR BEST POSTER PRESENTATION AWARDS

Presented by: Xin Sun, PhD, Professor, Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China



Sun

ISPOR 8TH ASIA-PACIFIC CONFERENCE ANNOUNCEMENT

Takashi Fukuda, PhD, Director, Department of Health and Welfare Services, National Institute of Public Health, Saitama, Japan



Fukuda

ISPOR 7TH ASIA-PACIFIC CONFERENCE REMARKS

Speakers: Wai Keung Chui, PhD, PhD, Associate Professor, Department of Pharmacy, National University of Singapore, Singapore

Syed Aljunid, MD, PhD, Professor, Health Economics and Public Health Medicine & Head, International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia

Ahmad Fuad Afdhal, PhD, Director, Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia



Chui



Aljunid



Afdhal

1:00PM-4:00PM **LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III Nicoll 1-3**

1:30PM-2:30PM **EDUCATIONAL SYMPOSIUM Summit 1**

HEALTH TECHNOLOGY ASSESSMENT POLICY SURROUNDING BIOLOGIC TREATMENTS IN IMMUNOLOGY: CHALLENGES AND OPPORTUNITIES

Sponsored by Eli Lilly & Company



2:00PM-3:00PM **RESEARCH POSTER AUTHOR DISCUSSION HOUR – SESSION III Nicoll 1-3**

2:45PM-3:45PM **EDUCATIONAL SYMPOSIUM Summit 1**

THE ROLE OF HTA IN HEALTH CARE DECISION MAKING

Sponsored by MSD



ISPOR 7TH ASIA-PACIFIC CONFERENCE

3-6 SEPTEMBER 2016 • SUNTEC SINGAPORE CONVENTION & EXHIBITION CENTER, SINGAPORE

PROGRAM & SCHEDULE OF EVENTS: TUESDAY, 6 SEPTEMBER

4:00PM-5:00PM **WORKSHOPS – SESSION III**

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W11: MARKET ACCESS OF ORPHAN DRUGS IN ASIA: RECENT DEVELOPMENTS AND IMPLICATIONS Summit 1

Discussion Leaders: **Xia Chen, PhD**, Senior Consultant, Market Access, Pope Woodhead & Associates, Cambridgeshire, UK; **Francois Lucas, PhD**, Principal Consultant, Pope Woodhead & Associates Ltd, St. Ives, UK; **Shanlian Hu, MS, MD**, Director, Shanghai Health Development Research Center, Shanghai, China; **Oswald Bentinck, LL.M, MSc**, Regional Market Access Lead, JAPAC & Aus/NZ, Shire, Zug, Switzerland

USE OF REAL WORLD DATA

W12: INTRODUCING A NOVEL CONCEPT TO OBSERVATIONAL RESEARCH IN THE ASIA-PACIFIC REGION: ENRICHED REAL-WORLD DATA STUDIES Room 300-301

Discussion Leaders: **Laura Garcia Alvarez, PhD**, Engagement Manager, Real-World Evidence Solutions, IMS Health, Barcelona, Spain; **Joshua Hiller, MBA**, Senior Principal, Real-World Evidence Solutions, IMS Health, London, UK; **Joanne Yoong, PhD**, Senior Economist, University of Southern California and Associate Professor, National University of Singapore (NUS), Singapore; **Ong Leong Seng, MSc**, Chief Architect & Group Director, Architecture & Innovation, Integrated Health Information System, Ministry of Health Holdings, Singapore

W13: EXPERIENCE IN PASS AND PAES IN EUROPE (2012-2015): POTENTIAL LESSONS FOR JAPAN Room 326

Discussion Leaders: **Michelle Bulliard, RN**, Vice President & Global Head, Real World Evidence Strategy, Quintiles, St Prex, Switzerland; **Tiphaine Courbet, MA**, Associate Director, Clinical Project Management, Regional Strategy Lead for APAC, Real World and Late Phase Research, Quintiles, Chatswood, Australia

ECONOMIC OUTCOMES RESEARCH

W14: DATA TRANSFERABILITY ACROSS ASIAN MARKETS: RESEARCH NEEDS FROM THE DECISION-MAKER AND INDUSTRY PERSPECTIVES Room 324

Discussion Leaders: **Joe Caputo, BSc**, Associate Director, ESSEC Institute of Health Economics and Management, ESSEC Asia-Pacific, Singapore; **Rob Thwaites, MA**, Senior Director, Takeda, London, UK

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

W15: BEYOND PATIENT COMPLIANCE AND ADHERENCE TO TREATMENT Room 325

Discussion Leaders: **Yi Han, PhD, MBA**, Executive Vice President, Market Access and HEOR, Cello Health, Yardley, PA, USA; **Hengjin Dong, PhD**, Executive Director, Center for Health Policy Studies, School of Public Health, Zhejiang University, Hangzhou, China; **Bruce C.M. Wang, PhD**, Chief Executive Officer, Elysia Group Ltd, Taipei, Taiwan; **Boxiong Tang, MD, PhD**, Senior Director, Global Health Economics and Outcomes Research, Teva Pharmaceutical, Frazer, PA, USA